Becton, Dickinson and Company $BDX Shares Bought by Public Sector Pension Investment Board

Public Sector Pension Investment Board lifted its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 14.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 25,108 shares of the medical instruments supplier’s stock after acquiring an additional 3,127 shares during the quarter. Public Sector Pension Investment Board’s holdings in Becton, Dickinson and Company were worth $4,699,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC grew its position in Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after acquiring an additional 877 shares during the period. RiverGlades Family Offices LLC acquired a new position in shares of Becton, Dickinson and Company in the 2nd quarter valued at about $344,000. Oppenheimer Asset Management Inc. grew its holdings in shares of Becton, Dickinson and Company by 71.4% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 82,655 shares of the medical instruments supplier’s stock worth $15,471,000 after purchasing an additional 34,437 shares during the period. Transcend Capital Advisors LLC increased its position in Becton, Dickinson and Company by 88.2% during the 3rd quarter. Transcend Capital Advisors LLC now owns 5,794 shares of the medical instruments supplier’s stock worth $1,084,000 after purchasing an additional 2,715 shares in the last quarter. Finally, Belpointe Asset Management LLC purchased a new position in Becton, Dickinson and Company in the third quarter valued at approximately $650,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on BDX. Wall Street Zen lowered shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Jefferies Financial Group lowered their price target on Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating for the company in a report on Tuesday, February 10th. Stifel Nicolaus boosted their price objective on Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a research note on Wednesday, January 7th. Royal Bank Of Canada set a $172.00 target price on Becton, Dickinson and Company in a research report on Tuesday, February 10th. Finally, Morgan Stanley raised their target price on Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a report on Tuesday, December 2nd. Five research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of “Hold” and an average target price of $195.46.

Insider Activity

In other news, Director Bertram L. Scott sold 953 shares of the company’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total value of $174,027.33. Following the sale, the director owned 36,763 shares in the company, valued at approximately $6,713,291.43. This represents a 2.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Michael David Garrison sold 1,610 shares of the business’s stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $207.46, for a total value of $334,010.60. Following the completion of the sale, the executive vice president directly owned 12,095 shares of the company’s stock, valued at approximately $2,509,228.70. This represents a 11.75% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 3,416 shares of company stock valued at $675,557 in the last three months. Insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Trading Down 0.2%

NYSE:BDX opened at $182.29 on Friday. The stock has a market cap of $51.91 billion, a price-to-earnings ratio of 29.74, a price-to-earnings-growth ratio of 13.24 and a beta of 0.25. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $185.02. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.58 and a current ratio of 1.05. The business’s 50-day simple moving average is $197.64 and its 200 day simple moving average is $192.19.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.81 by $0.10. The company had revenue of $5.25 billion for the quarter, compared to the consensus estimate of $5.15 billion. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.Becton, Dickinson and Company’s revenue for the quarter was up 1.6% compared to the same quarter last year. During the same period in the previous year, the business earned $3.43 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. As a group, sell-side analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th will be issued a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend is Tuesday, March 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 68.52%.

Becton, Dickinson and Company announced that its board has authorized a stock repurchase plan on Tuesday, January 27th that allows the company to buyback $10.00 million in shares. This buyback authorization allows the medical instruments supplier to reacquire up to 0% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s board of directors believes its shares are undervalued.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.